HY-156769 Search Results


rg7388 idasanutlin  (MedChemExpress)
95
MedChemExpress rg7388 idasanutlin
ALRN-6924 anti-proliferative efficacy in vitro . a – c Cell line panel screening. Two cancer cell line panels (Eurofins OncoPanel and focused Horizons Discovery OncoSignature panel) of total 302 cell lines were employed to assess ALRN-6924 activity ( a ). Horizons Discovery OncoSignature panel of 89 cell lines was used to compare three MDM2/MDM4 inhibitors, ALRN-6924, RG7112, and <t>RG7388</t> ( b ). The effect of ALRN-6924 on breast cancer was assessed in 23 breast cancer cell lines ( c ). For these screening assay ( a – c ), cells seeded into 384-well plates overnight were treated the inhibitors at serially diluted concentrations for 72 h. EC 50 (equally IC 50 , half-maximal inhibitory concentration) was determined using relative cell proliferation rate assessed by changes in nuclear dye uptake or ATP levels. d Effect of ALRN-6924 on breast cancer cell lines with different ER status. Cells, seeded in 96-well plates, were treated with ALRN-6924 at serially diluted concentrations for 72 h. Cell proliferation was determined using SRB assay. IC 50 was calculated using CalcuSyn. Data represent mean ± SD obtained from three replicates. e – h Colony formation assay. ER+ breast cancer cell lines MCF-7 ( e , f ) and ZR-75-1 ( g , h ), seeded in 6-well plates, were cultured in the presence of vehicle or ALRN-6924 at different concentrations for 2–3 weeks followed by crystal violet staining. Colony images show representative wells ( e , g ). Total colony area (pixel^2) was measured by using NIH ImageJ software ( f , h ). Data represent mean ± SD from triplicates
Rg7388 Idasanutlin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rg7388 idasanutlin/product/MedChemExpress
Average 95 stars, based on 1 article reviews
rg7388 idasanutlin - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

Image Search Results


ALRN-6924 anti-proliferative efficacy in vitro . a – c Cell line panel screening. Two cancer cell line panels (Eurofins OncoPanel and focused Horizons Discovery OncoSignature panel) of total 302 cell lines were employed to assess ALRN-6924 activity ( a ). Horizons Discovery OncoSignature panel of 89 cell lines was used to compare three MDM2/MDM4 inhibitors, ALRN-6924, RG7112, and RG7388 ( b ). The effect of ALRN-6924 on breast cancer was assessed in 23 breast cancer cell lines ( c ). For these screening assay ( a – c ), cells seeded into 384-well plates overnight were treated the inhibitors at serially diluted concentrations for 72 h. EC 50 (equally IC 50 , half-maximal inhibitory concentration) was determined using relative cell proliferation rate assessed by changes in nuclear dye uptake or ATP levels. d Effect of ALRN-6924 on breast cancer cell lines with different ER status. Cells, seeded in 96-well plates, were treated with ALRN-6924 at serially diluted concentrations for 72 h. Cell proliferation was determined using SRB assay. IC 50 was calculated using CalcuSyn. Data represent mean ± SD obtained from three replicates. e – h Colony formation assay. ER+ breast cancer cell lines MCF-7 ( e , f ) and ZR-75-1 ( g , h ), seeded in 6-well plates, were cultured in the presence of vehicle or ALRN-6924 at different concentrations for 2–3 weeks followed by crystal violet staining. Colony images show representative wells ( e , g ). Total colony area (pixel^2) was measured by using NIH ImageJ software ( f , h ). Data represent mean ± SD from triplicates

Journal: Breast Cancer Research : BCR

Article Title: First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

doi: 10.1186/s13058-021-01406-x

Figure Lengend Snippet: ALRN-6924 anti-proliferative efficacy in vitro . a – c Cell line panel screening. Two cancer cell line panels (Eurofins OncoPanel and focused Horizons Discovery OncoSignature panel) of total 302 cell lines were employed to assess ALRN-6924 activity ( a ). Horizons Discovery OncoSignature panel of 89 cell lines was used to compare three MDM2/MDM4 inhibitors, ALRN-6924, RG7112, and RG7388 ( b ). The effect of ALRN-6924 on breast cancer was assessed in 23 breast cancer cell lines ( c ). For these screening assay ( a – c ), cells seeded into 384-well plates overnight were treated the inhibitors at serially diluted concentrations for 72 h. EC 50 (equally IC 50 , half-maximal inhibitory concentration) was determined using relative cell proliferation rate assessed by changes in nuclear dye uptake or ATP levels. d Effect of ALRN-6924 on breast cancer cell lines with different ER status. Cells, seeded in 96-well plates, were treated with ALRN-6924 at serially diluted concentrations for 72 h. Cell proliferation was determined using SRB assay. IC 50 was calculated using CalcuSyn. Data represent mean ± SD obtained from three replicates. e – h Colony formation assay. ER+ breast cancer cell lines MCF-7 ( e , f ) and ZR-75-1 ( g , h ), seeded in 6-well plates, were cultured in the presence of vehicle or ALRN-6924 at different concentrations for 2–3 weeks followed by crystal violet staining. Colony images show representative wells ( e , g ). Total colony area (pixel^2) was measured by using NIH ImageJ software ( f , h ). Data represent mean ± SD from triplicates

Article Snippet: RG7112 and RG7388 (idasanutlin) and paclitaxel were purchased for in vitro studies from MedChemExpress (Monmouth Junction, NJ, USA).

Techniques: In Vitro, Activity Assay, Screening Assay, Concentration Assay, Sulforhodamine B Assay, Colony Assay, Cell Culture, Staining, Software